Clinical trial
Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung…
NCT00154739 · National Taiwan University Hospital, Other · Completed
Key facts
| NCT number | NCT00154739 |
|---|---|
| Title | Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase II Randomized Trial of Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin in Stage IIIB/IV Non-Small Cell Lung Cancer |
| Lead sponsor | National Taiwan University Hospital, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Cisplatin, Epirubicin |
| Enrollment | 86 |
| Start date | Oct 1, 1998 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Aug 4, 2008 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: